Navigation Links
New drug significantly lowers bad cholesterol
Date:11/6/2012

BOSTON, MAFor many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.

Now researchers at Brigham and Women's Hospital have shown that in patients already on a statin, the addition of a new drug, called AMG 145, can reduce LDL cholesterol levels by up to 66 percent after 12 weeks.

The study was presented at the 2012 American Heart Association Scientific Sessions and electronically published in Lancet on November 6, 2012.

In a double-blind, dose-ranging, placebo-controlled study, 631 patients ages 18 to 80 years old with high cholesterol on a stable statin dose (with or without ezetimibe) were randomized to receive one of six different AMG 145 dose regimens or matching placebo. The treatments were given subcutaneously (an injection under the skin) every two or every four weeks for a total of twelve weeks.

In participants who received AMG 145 every two weeks, the drug reduced LDL cholesterol in a dose-dependent manner by 42 to 66 percent at the end of twelve weeks compared to placebo.

For those taking AMG 145 every four weeks, the drug reduced LDL cholesterol in a dose-dependent manner by 42 to 50 percent at the end of twelve weeks compared to placebo. Moreover, just one week after a dose, researchers saw LDL cholesterol reduced by up to 85 percent.

"The observed reductions in LDL cholesterol are extraordinary, especially when one considers that they are seen on top of statin therapy," said Robert Giugliano, MD, BWH Cardiovascular Division, Department of Medicine, investigator for the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and lead study author.

The highest dose given every two weeks also allowed 93.5 percent of patients to achieve the most stringent cholesterol-lowering goals. Furthermore, the researchers noted that there were no serious adverse events that occurred with AMG 145 treatment.

"These data are very exciting and may offer a new paradigm for LDL cholesterol reduction. The next step will be a large-scale, long-term cardiovascular outcomes trial," said Marc Sabatine, MD, chairman of the TIMI Study Group, and senior study author.

AMG 145 is a monoclonal antibody. It binds to a protein that normally shepherds LDL cholesterol receptors for destruction. By blocking that protein, AMG 145 protects the receptors from being destroyed, thereby increasing the number of LDL cholesterol receptors on the surface of the liver that help remove bad cholesterol from the bloodstream.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Rheumatic heart disease is significantly under-treated in Africa and India
2. Canada should significantly increase its funding of randomized clinical trials
3. Lowering the national ozone standard would significantly reduce mortality and morbidity
4. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
5. Study: Vaccine targets malignant brain cancer antigens, significantly lengthens survival
6. Non-invasive diagnostic imaging costs to Medicare Part B down significantly since 2006
7. Marital status, race increase survival rate significantly for Stage III non-small cell lung cancer patients
8. Only children are significantly more likely to be overweight
9. Outpatient urological surgery costs significantly less when performed in physician offices & ACCs
10. Drug doesnt significantly lower risk of major heart problems in dialysis patients
11. Modest alcohol consumption lowers risk and severity of liver disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: